Alkol Madde Kullanım Bozukluklarında Laboratuvar ve Nörogörüntüleme Yöntemleri
Özet
Bu metin, alkol ve madde kullanım bozukluklarının tanı ve takip süreçlerinde kullanılan laboratuvar ve nörogörüntüleme yöntemlerini kapsamlı bir şekilde ele almaktadır. Laboratuvar boyutunda, etanol analizinde kullanılan enzim aktivitesine bağlı yöntemlerin otomasyona uygun ve ucuz olduğu, ancak yüksek laktat/LDH seviyeleri ile diğer toksik alkollerden kaynaklanan interferanslar nedeniyle yalancı pozitiflik oluşturabildiği belirtilmektedir. Bu hataları önlemek için osmolal gap, CDT/transferrin oranı ve idrar bütünlük testleri gibi ek parametreler ile doğrulama analizleri (GC-MS, LC-MS/MS) önerilmektedir. Klinik uygulamalarda yaygın olarak kullanılan idrar madde analizlerinde amfetamin, kokain, opiyat, esrar ve benzodiazepin gibi maddelerin taranmasında cut-off değerleri ile çeşitli ilaçların yol açtığı çapraz reaksiyonlar ve hileli müdahaleler incelenmektedir. Nörogörüntüleme kısmında ise fMRG, PET, SPECT, H-MRS ve DTG tekniklerinin bağımlılık mekanizmalarını anlamadaki rolü vurgulanmaktadır. fMRG aşerme ve dürtüselliği, PET/SPECT dopamin yolakları ve glukoz metabolizmasını, H-MRS glutamat homeostazını, DTG ise özellikle kronik kullanımda beyaz cevher hasarını saptamada önemli veriler sunmaktadır. Sonuç olarak, laboratuvar testleri günlük ve adli pratikte sıkça kullanılırken, nörogörüntüleme yöntemlerinin maliyetleri azaldıkça klinik araştırmalardan yaygın tanısal kullanıma evrilmesi beklenmektedir.
This text comprehensively examines the laboratory and neuroimaging methods used in the diagnosis and follow-up processes of alcohol and substance use disorders. On the laboratory side, it is stated that enzymatic measurement methods used in ethanol analysis are cost-effective and suitable for automation, yet they can cause false positivity due to interferences from high lactate/LDH levels and other toxic alcohols. To prevent these errors, supplementary parameters such as osmolal gap, CDT/transferrin ratio, and urine integrity tests, along with confirmatory analyses (GC-MS, LC-MS/MS), are recommended. In urine substance analyses widely used in clinical practice, cut-off values, cross-reactions caused by various medications, and fraudulent interventions in screening substances like amphetamines, cocaine, opiates, cannabis, and benzodiazepines are investigated. In the neuroimaging section, the role of fMRI, PET, SPECT, 1H-MRS, and DTI techniques in understanding addiction mechanisms is emphasized. fMRI provides crucial data on craving and impulsivity, PET/SPECT on dopamine pathways and glucose metabolism, 1H-MRS on glutamate homeostasis, and DTI on identifying white matter damage, particularly in chronic exposure. In conclusion, while laboratory tests are frequently utilized in daily and forensic practice, neuroimaging methods are expected to expand from clinical research into widespread diagnostic use as their costs decrease.
Referanslar
Pinar-Sanchez J., Bermejo López P, Solís García Del Pozo J, et al. Common Laboratory Parameters Are Useful for Screening for Alcohol Use Disorder: Designing a Predictive Model Using Machine Learning. Journal of clinical medicine. 2022; 11(7): 2061.
Friedmann PD. Clinical practice. Alcohol use in adults. NEnglJMed. 2013; 368 (4): 365–73.
Marcos Martín M. Encinas IP. I, Laso Guzmán FJ. Marcadores biológicos del alcoholismo. Rev Clin Esp. 2005; 205(9),:443-5.
Dawling S. Alcohol Determination Using Automated Analyzers: Limitations and Pitfalls. In Accurate Results in the Clinical Laboratory,Elsevier. 2013:247-272.
Tıbbi Laboratuvarlarda kan numunelerinde etanol analizi işlemleri Genelgesi (2017/12). (19.07.2022 tarihinde https://shgmtetkikdb.saglik.gov.tr/TR-32673 adresinden ulaşılmıştır).
Pietruszko R, Crawford K, Lester D. Comparison of substrate specificity of alcohol dehydrogenases from human liver, horse liver, and yeast towards saturated and 2-enoic alcohols and aldehydes. Archives of Biochemistry and Biophysics. 1973; 159(1): 50-60.
Green DW, Sun HW, Plapp BV. Inversion of the substrate specificity of yeast alcohol dehydrogenase. Journal of Biological Chemistry.1993; 268(11):7792-7798.
Gharapetian A, Holmes DT, Urquhart, et al. Dehydrogenase interference with enzymatic ethanol assays: forgotten but not gone. Clinical chemistry. 2008;54(7):1251-1252.
Purssel RA, Pudek M, Brubacher J. Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap. Annals of emergency medicine. 2001;38(6): 653-659.
Smithline N, Gardner KD. Gaps—anionic and osmolal. JAMA.1976;236(14):1594-1597.
Böttcher M, Beck O, Helander A. Evaluation of a new immunoassay for urinary ethyl glucuronide testing. Alcohol & Alcoholism. 2008; 43(1):46-48.
Neumann T, Helander A, Dahl H, et al. Value of ethyl glucuronide in plasma as a biomarker for recent alcohol consumption in the emergency room. Alcohol & Alcoholism. 2008; 43(4):431-435.
Silczuk A, Habrat B. Alcohol-induced thrombocytopenia: Current review. Alcohol.2020; 86: 9-16.
Deas D, Johnson N, Thomas S. Carbohydrate deficient transferrin (CDT) predicts heavy drinking in adolescents with alcohol dependence. Alcohol. 2019;81:27-30.
Watson ID, Hammett-Stabler C, Nicholes B, et al. Drugs and ethanol. In: J.H.Nichols (Ed). Laboratory medicine practice guidelines:Evidence-based practice for point-of-care testing. Washington: National Academy of Clinical Biochemistry. 2006. p. 63–75.
Kılınçkaya M. İN. Madde Analizleri ve Yönetimi Genel Prensipler Rehberi. İçinde: Dildar Konukoğlu, Necip İlhan TT (Ed). Ankara: Palme Kitabevi; 2017. p. 80–95.
Costantino AG, Altomare C, Stella A. Issues of false negative results in toxicology: difficult in detecting certain drugs and issues with detection of synthetic cathinone (bath salts), synthetic cannabinoids (spice), and other new psychoactive substances. In Accurate Results in the Clinical Laboratory; Elsevier.2019.p. 257-270.
“İdrar Numunelerinde Yasadışı ve Kötüye Kullanılan İlaç ve Madde Analizi Yapan Tıbbi Laboratuvarlar ile Madde Bağımlılığı Teşhis ve Tedavi Merkezlerindeki Tıbbi Laboratuvarların İşleyiş Esasları” https://shgmtetkikdb.saglik.gov.tr/TR-12325/idrar-numunelerinde-yasadisi-ve-kotuye-kullanilan-ilac-ve-madde-analizi-yapan-tibbi-laboratuvarlar-ile-madde-bagimliligi-teshis-ve-tedavi-merkezlerindeki-tibbi-laboratuvarlarin-isleyis-esaslari-yayinlandi.html (15.07.2022 tarihinde ulaşılmıştır).
Dasgupta, A. The effects of adult erants and selected ingested compounds on drugs-of-abuse testing in urine. American Journal of Clinical Pathology.2007; 128(3):491-503.
Fu, S. Adulterants in urine drug testing. In Advances in clinical chemistry, Elsevier.2016. p. 123-163.
Urry FM, Komaromy-Hiller G, Staley B et al. Nitrite adulteration of workplace urine drug-testing specimens I. Sources and associated concentrations of nitrite in urine and distinction between natural sources and adulteration. Journal of analytical toxicology.1998; 22(2):89-95.
Broussard LA. Challenges in confirmation testing for drugs of abuse. In Accurate Results in the Clinical Laboratory; Elsevier.2017.p 243-256.
Eichhorst JC, Etter ML, Rousseaux N, et al. Drugs of abuse testing by tandem mass spectrometry: a rapid, simple method to replace immunoassays. Clinical Biochemistry. 2009;42(15):1531-1542.
Maralikova B, Weinmann W. Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography–tandem mass spectrometry with respect to criteria for compound identification. Journal of Chromatography B.2004; 811(1):21-30.
Nieddu M, Baralla E, Pasciu, V, et al.Cross-Reactivity of Commercial Immunoassays for Screening of New Amphetamine Designer Drugs. A Review. Journal of Pharmaceutical and Biomedical Analysis,2022. 114868.
Boyd JM, Sadrzadeh SH. Limitations of immunoassays for screening of drugs of abuse in urine: issues of false positive and false negative results. In Accurate Results in the Clinical Laboratory. Elsevier, 2019. p. 233-242.
Ewald AH, Fritschi G, Bork WR, et al. Designer drugs 2, 5‐dimethoxy‐4‐bromo‐amphetamine (DOB) and 2, 5‐dimethoxy‐4‐bromo‐methamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. Journal of mass spectrometry. 2006; 41(4): 487-498.
Kerrigan S, Banuelos S, Perrella L, et al. Simultaneous detection of ten psychedelic phenethylamines in urine by gas chromatography-mass spectrometry. Journal of analytical toxicology. 2011;35(7): 459-469.
Cohen PA. Imported fenproporex-based diet pills from Brazil: a report of two cases. Journal of general internal medicine. 2009; 24(3):430-433.
Armbruster DA, Schwarzhoff RH, Hubster EC, et al. Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening. Clinical chemistry. 1993;39(10):2137-2146.
Goldberger BA, Cone EJ. Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry. Journal of chromatography A. 1994;674(1-2):73-86.
Kronstrand R, Nyström I, Andersson M, et al. Urinary detection times and metabolite/parent compound ratios after a single dose of buprenorphine. Journal of analytical toxicology. 2008;32(8): 586-593.
White RM, Black ML. Pain management testing reference. American Association for Clinical Chemistry. 2007.
Rengarajan A, Mullins ME. How often do false-positive phencyclidine urine screens occur with use of common medications?. Clinical Toxicology. 2013;51(6):493-496.
Nasky KM, Cowan GL, Knittel DR. False-positive urine screening for benzodiazepines: an association with sertraline?: a two-year retrospective chart analysis. Psychiatry (Edgmont).2009; 6(7):36.
What can cause a false positive urine drug screening for benzodiazepines? https://www.practicalpainmanagement.com/resources/diagnostic-tests/ask-expert-false-positive-screen-benzodiazepines
Abou-Saleh MT. Neuroimaging in psychiatry: an update. Journal of Psychosomatic Research. 2006; 61(3): 289-293.
Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology. 2004; 47:3-13.
Linden DE. The challenges and promise of neuroimaging in psychiatry. Neuron. 2012;73(1): 8-22.
Hamdi E, Al-Suhaili A, Abou-Saleh MT, et al. Cerebral blood flow in alcohol withdrawal: Relation to severity of dependence and cognitive impairment. Acta Neuropsychiatrica. 2003;15(2):55–62.
Emre H, Ulaş AY, Hüden N, ve ark. Rezonans Görüntüleme Temelli Fonksiyonel Bağlantısallık Yöntemleri. Journal of Istanbul Faculty of Medicine. 2020;83(1):71-80.
Courtney KE, Schacht JP, Hutchison K. et al. Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addiction biology. 2016; 21(1): 3-22.
Cousijn J, Wiers RW, Ridderinkhof KR, et al. Individual differences in decision making and reward processing predict changes in cannabis use: a prospective functional magnetic resonance imaging study. Addiction biology. 2013;18(6):1013-1023.
Krienke UJ, Nikesch F, Spiegelhalder K, et al. Impact of alcohol-related video sequences on functional MRI in abstinent alcoholics. European Addiction Research. 2014; 20(1):33-40.
Schacht JP, Anton RF, Myrick H. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta‐analysis and systematic review. Addiction biology. 2013; 18(1):121-133.
Bednarski SR, Erdman E, Luo X, et al. Neural processes of an indirect analog of risk taking in young nondependent adult alcohol drinkers—an fMRI study of the stop signal task. Alcoholism: Clinical and Experimental Research. 2012;36(5):768-779.
Langosch JM, Spiegelhalder K, Jahnke K, et al. The impact of acamprosate on cue reactivity in alcohol dependent individuals: a functional magnetic resonance imaging study. Journal of clinical psychopharmacology.2012; 32(5):661-665.
Lukas SE, Lowen SB, Lindsey KP, et al.Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Neuroimage.2013; 78:176-185.
Imam SK. Molecular nuclear imaging: The radiopharmaceuticals (review). Cancer biotherapy & radiopharmaceuticals. 2005;20(2):163–72.
Karaçavuş S. Imaging Modalities Used in Preclinical Studies. Nukleer Tıp Seminerleri. 2019;5(1): 23.
Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology,. 2004;47:3-13.
Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. American Journal of Psychiatry. 2005;162(8):1403-1413.
Cabrera EA, Wiers CE, Lindgren E, et al. Neuroimaging the Effectiveness of Substance Use Disorder Treatments. Journal of Neuroimmune Pharmacology. 2016 Sep 1;11(3):408–33.
London ED, Kohno M, Morales AM, et al. Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. Brain research. 2015; 1628:174-185.
Wang GJ, Volkow ND, Chang L, et al. Partial Recovery of Brain Metabolism in Methamphetamine Abusers after Protracted Abstinence. American Journal of Psychiatry.2004;161(2):242–8.
Spreckelmeyer KN, Paulzen M, Raptis M, et al. Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [18F] fallypride positron emission tomography study. Biological psychiatry. 2011; 70(8):770-776.
Chang L, Munsaka SM, Kraft-Terry S, et al. Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. Journal of Neuroimmune Pharmacology.2013; 8(3):576-593.
Reissner KJ, Kalivas PW. Using glutamate homeostasis as a target for treating addictive disorders. Behavioural pharmacology. 2010;21(5–6):514–22.
Hermann D, Frischknecht U, HeinrichM, et al. MR spectroscopy in opiate maintenance therapy: association of glutamate with the number of previous withdrawals in the anterior cingulate cortex. Addiction biology.2012;17(3): 659-667.
Li R, Ma Z, Yu J, et al. Altered local activity and functional connectivity of the anterior cingulate cortex in elderly individuals with subthreshold depression. Psychiatry Research: NeuroImaging. 2014;222(1-2):29-36.
Yang S, Salmeron BJ, Ross TJ, et al. Lower glutamate levels in rostral anterior cingulate of chronic cocaine users—A 1H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy. Psychiatry Research: Neuroimaging, 2009;174(3): 171-176.
Liu X, Jensen JE, Gillis TE, et al. Chronic cocaine exposure induces putamen glutamate and glutamine metabolite abnormalities in squirrel monkeys. Psychopharmacology. 2011;217(3):367–75.
Zahr NM, Kaufman KL, Harper CG. Clinical and pathological features of alcohol-related brain damage. Nature Reviews Neurology. 2011, 7(5):284-294.
Bora, E, Yücel M, Fornito A, et al. White matter microstructure in opiate addiction. Addiction biology. 2012;17(1):141-148.
